We have studied the ability of the androgen etiocholanolone and its enantiomer (entetiocholanolone) to modulate the rat α1β2γ2L GABA A receptor function transiently expressed in HEK cells. Studies on steroid enantiomer pairs can yield powerful new information on the pharmacology of steroid interactions with the GABA A receptor. Both steroids enhance currents elicited by GABA but ent-etiocholanolone is much more powerful than etiocholanolone at producing potentiation. At a low GABA concentration (0.5 µM, <EC 5 ), the presence of 10 µM entetiocholanolone potentiates whole-cell currents by almost 30-fold while 10 µM etiocholanolone merely doubles the peak response. At higher GABA concentration (5 µM, ~EC 25 ), the potentiation curve for ent-etiocholanolone is positioned at lower concentrations than that for etiocholanolone.
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INTRODUCTION
Potentiating steroids modulate GABA A receptor activity via interactions with binding sites located within the membraneous domains of the receptor (Rick et al., 1998; Akk et al., 2005; Hosie et al., 2006) . The existing electrophysiological data support three distinct, but possibly allosterically coupled, sites for steroids, each influencing a distinct kinetic aspect of channel activation. Two parameters of channel openings (the duration and fraction of long openings) and one parameter of channel closings (the fraction of the activation-related closed time) are affected upon exposure to many neuroactive steroids (Twyman and Macdonald, 1992; Akk et al., 2004) . The structural basis of steroid potentiation is much less well understood. Recent data pinpoint a potentiating steroid site in a cavity between the M1 and M4 transmembrane domains in the α subunit where specific residues act as hydrogen bond donor and acceptor to stabilize the steroid molecule (Hosie et al., 2006) . Despite this obviously important finding, it remains unresolved whether this site represents a common interaction site for potentiating steroids or whether structurally diverse steroids interact with distinct, although possibly overlapping, binding sites, and how the identified site relates to the multiple kinetic effects observed for steroids.
An enantiomer is a stereoisomer of an optically active compound in which all chiral centers have the opposite configuration resulting in a mirror image of itself. As a result, the steroids of an enantiomer pair have identical chemical and physical properties (i.e., interactions with the lipid membrane) but may differ in their ability to interact with specialized binding pockets on receptors or other targets with chiral centers. Previous work has established that the actions of many steroids on the GABA A receptor are enantioselective. For example, the enantiomers of endogenous neurosteroids allopregnanolone and pregnanolone are weaker potentiators of receptor function than the natural steroids (Covey et al., 2000) . In contrast, enantiomers of androsterone and etiocholanolone are more effective at modulating the GABA A receptor function than the natural steroids (Katona et al., submitted) . The enantioselectivity of steroid modulators is not limited to the GABA A receptor. In the related GABA C receptor, pregnanolone blocks receptor This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on March 6, 2007 as DOI: 10.1124 at ASPET Journals on October 29, 2017 molpharm.aspetjournals.org Downloaded from activation by GABA, but its enantiomer acts as a potentiator (Li et al., 2006b) . Human nicotinic α4β2 receptors are potentiated by 17β-estradiol but not by its enantiomer (Paradiso et al., 2001 ).
Finally, the block of T-type Ca 2+ channels by (3β,5α,17β)-17-hydroxyestrane-3-carbonitrile has been shown to be enantioselective (Todorovic et al., 1998) .
Two interpretations for enantioselectivity have been put forward. First, the differences in the actions of natural and enantiomer steroids have been interpreted as rising from non-optimal interactions between a common chiral binding pocket and one of the steroids within the enantiomer pair. Another interpretation is that interactions with distinct binding sites underlie the actions of natural and enantiomer steroids, and that the ability to efficiently interact with their individual sites determines the potency and efficacy of the steroids within an enantiomer pair (Katona et al., submitted; Wittmer et al., 1996) .
In this manuscript, we present results from studies on channel modulation by the androgen, etiocholanolone and its enantiomer. This pair of steroids is uncommon in that the enantiomer is a stronger potentiator of the GABA A receptor than the natural isomer. We introduce data indicating that the natural and enantiomer versions of etiocholanolone potentiate the GABA A receptor via different kinetic mechanisms, and that steroid interactions with distinct sites underlie their effects.
MATERIALS AND METHODS
Experiments were conducted on HEK293 cells (ATCC Number CRL-1573) expressing rat α 1β2γ2L GABA A receptors as described previously (Akk et al., 2001; 2004; Li et al., 2006a) . The subunit cDNAs were subcloned into the pcDNA3 expression vector (Invitrogen, Carlsbad, CA) and expressed in HEK cells using a calcium phosphate precipitation-based transient transfection technique (Akk, 2002) . The α1 subunit is epitope (FLAG) tagged in the aminoterminal end of the subunit (Einhauer and Jungbauer, 2001; Ueno et al., 1996) . The presence of the FLAG tag is without effect on channel kinetics (Ueno et al., 1996; unpublished observations) .
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The experiments were carried out using standard single-channel patch clamp and wholecell voltage clamp methods. The bath solution contained (in mM): 140 NaCl, 5 KCl, 1 MgCl 2 , 2 CaCl 2 , 10 glucose and 10 HEPES; pH 7.4. In single-channel recordings, the pipet solution contained (in mM): 120 NaCl, 5 KCl, 10 MgCl 2 , 0.1 CaCl 2 , 20 tetraethylammonium, 5 4-aminopyridine, 10 glucose, 10 HEPES; pH 7.4. In whole-cell recordings, the pipet solution contained (in mM): 140 CsCl, 4 NaCl, 4 MgCl 2 , 0.5 CaCl 2 , 5 EGTA, 10 HEPES, pH 7.4.
The agonist (GABA) and steroid modulators were added to the pipet solution in singlechannel recordings, or applied through the bath using an SF-77B fast perfusion stepper system (Warner Instruments, Hamden, CT) in whole-cell experiments.The steroids were initially dissolved in DMSO at 10 mM concentration, and diluted immediately before the experiment. The maximal DMSO concentration in diluted steroid solutions was 0.3 %. Channel activation by GABA was not affected by the presence of 0.3 % DMSO (data not shown). All experiments were carried out at room temperature.
The recording and analysis of single-channel currents have been described in detail previously (Akk et al., 2001; 2004) . All currents were obtained at 50 µM GABA, a concentration which corresponds to approximately EC 30 in the open probability dose-response curve (Steinbach and Akk, 2001 ). The pipet potential was held at +60 to +80 mV, which translates to an approximately -120 to -100 mV potential difference across the patch membrane. The channel activity was recorded using an Axopatch 200B amplifier, low-pass filtered at 10 kHz, and acquired with a Digidata 1320 series interface at 50 kHz using pClamp software (Molecular Devices, Union City, CA). The key features of the analysis of single-channel currents are the following. The analysis was limited to clusters, i.e., episodes of intense activity originating from the activation of a single ion channel, or fragments of clusters containing no overlapping currents. The currents were low-pass filtered at 2-3 kHz, and the data were idealized using the segmented-k-means algorithm (Qin et al., 1996) . The open and closed times were estimated from the idealized currents using a maximum likelihood method which incorporates a correction for missed events (QuB Suite;
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The recording and analysis of whole-cell currents was carried out as described previously (Li et al., 2006a) . The cells were clamped at -60 mV. The cells were exposed to GABA and steroids for 4 s with 30 s washouts separating successive applications. The current traces were low-pass filtered at 2 kHz and digitized at 10 kHz. The analysis of whole-cell currents was carried out using the pClamp 9.0 software package, and was aimed at determining the peak amplitude.
The enantiomer of etiocholanolone was synthesized as described in Katona et al. (submitted) . Etiocholanolone, 3α5βP and other chemicals were purchased from Sigma Chemical Co (St Louis, MO).
RESULTS
Different kinetic actions underly the ability of etiocholanolone and its enantiomer to potentiate the GABA A receptor
While both natural and ent-etiocholanolone can potentiate receptor activity elicited by GABA, the enantiomer is much stronger at doing so than its natural counterpart. When coapplied with 0.5 µM GABA (<EC 5 , Li et al., 2006a) , 10 µM ent-etiocholanolone results in 28±10-fold potentiation of whole-cell response compared to a 2.3±0.9-fold potentiation when 10 µM etiocholanolone is applied with GABA (n=6 cells). When the steroids are applied in the presence of 5 µM GABA (~EC 25 ), the potentiation dose-response curve for ent-etiocholanolone is shifted to lower steroid concentrations compared to the dose-response curve for etiocholanolone (Figure 1 ).
Single-channel recordings were carried out in the presence of natural and entetiocholanolone in order to determine the kinetic modes of action of the steroids. Our previous studies have shown that exposure to potentiating neuroactive steroids can result in three distinct kinetic effects on GABA A receptor currents (Akk et al., 2004; Sample currents recorded at 50 µM GABA, in the absence and presence of 10 µM Figure 3B and the summary of the results is given in Tables 1-2 .
Different binding sites underlie actions of etiocholanolone and ent-etiocholanolone
A cavity within the α subunit that is lined by the N407/Y410 residues in its extracellular side has been proposed to constitute a binding pocket for steroids (Hosie et al., 2006) . The two residues have been suggested to interact with the D-ring of a steroid molecule, and mutations to these residues reduce potentiation by many steroids as well as a related tricyclic benz[e]indene steroid analogue (Hosie et al., 2006; Li et al., 2006a) . We examined the effects of α1(N407A/Y410F) mutations on receptor potentiation by etiocholanolone and ent-etiocholanolone.
Sample macroscopic recordings and the steroid dose-response curves are given in Figure 4 . The data indicate that the α1(N407A/Y410F) double mutation fully abolishes potentiation by the natural isomer at concentrations up to 30 µM. In contrast, potentiation by the enantiomer is shifted toward higher steroid concentrations but the efficacy of ent-etiocholanolone is unaffected by the double mutation. At face value, the simplest interpretation of the findings is that the binding site(s) for entetiocholanolone differ from the site for etiocholanolone, and that the α1(N407A/Y410F) double mutation most strongly affects the site through which etiocholanolone interacts with the receptor.
The data from single-channel recordings showed that ent-etiocholanolone and etiocholanolone interact with different classes of binding sites: ent-etiocholanolone influences kinetic effects mediated by Sites A1 and A2 while potentiation in the presence of etiocholanolone is achieved through steroid interactions with a single site (Site A2). Hence, an alternative explanation of the findings is that the α1(N407A/Y410F) double mutation affects only steroid interactions with Site A2 (fraction of OT3) and not those mediated by steroid interactions with Site A1. If so, then the double mutation can be expected to have a weaker effect on receptor potentiation by ent-etiocholanolone which utilizes the Site A1 pathway (fraction of CT3) in addition to the Site A2 pathway to potentiate receptor function, than on receptor potentiation by etiocholanolone which utilizes only the Site A2 pathway. This interpretation would be valid irrespective of whether Sites A1 and A2 are the same for etiocholanolone and ent-etiocholanolone.
To test this hypothesis, we examined the effect of the α1(N407A/Y410F) double mutation on channel potentiation by 3α5βP. In single-channel recordings, this steroid has been shown to possess all three kinetic effects on GABA A receptor activation (see above). Thus, a full exclusion This article has not been copyedited and formatted. The final version may differ from this version. of potentiation in the mutant receptor would imply that the double mutation is able to remove potentiation mediated by all three sites.
Sample currents and 3α5βP dose-response curves for wild-type and mutant receptors are shown in Figure 5 . The results demonstrate that the double mutation fully eliminates channel potentiation by 3α5βP demonstrating that the mutation is able to block steroid effects via all three sites. Conversely, the finding implies that the α1(N407A/Y410F) double mutation does not affect the interactions between ent-etiocholanolone and either Site A1 or Site A2, and that Site A2 for etiocholanolone is distinct from Site A2 for ent-etiocholanolone.
The hydroxyl group at the other end of the steroid molecule (A-ring) has been suggested to interact with the Q241 residue in the α1 subunit (Hosie et al., 2006) . We decided to test if a mutation to this site also differentially affects potentiation by etiocholanolone vs. entetiocholanolone. Macroscopic recordings were carried out at 5 µM GABA (~EC 5 , dose-response data not shown) in the absence and presence of 10 µM etiocholanolone or ent-etiocholanolone.
Sample recordings and the summary of findings are given in Figure 6 . The data demonstrate that the mutation fully abolishes modulation by etiocholanolone, while the enantiomer of etiocholanolone retains some ability to potentiate the current response. Application of 10 µM entetiocholanolone potentiated the peak current to 160±24 % of control (n=10 cells, p<0.001) while in the presence of etiocholanolone, the peak response was 112±13 % of control (n=5 cells, p>0.1).
We examined the effect of one other mutation on channel potentiation by the steroid pair.
The residue α1I238 has been proposed to line the steroid potentiation site, and substitution of the hydrophobic isoleucine with a polar asparagine has been shown to reduce steroid potency, presumably due to electrostatic repulsion (Hosie et al., 2006) . Macroscopic recordings were carried out at 0.2 µM GABA (~EC 5 , dose-response data not shown) in the absence and presence of 10 µM etiocholanolone or ent-etiocholanolone. Sample recordings and the summary of findings are given in Figure 6 . The data demonstrate that this mutation also differentially affects modulation suggest that steroid interactions with three separate interaction sites underlie channel potentiation (Li et al., 2006a) . Inhibition curves of t-butylbicyclophosphorothionate (TBPS) binding in the presence of steroids, similarly indicate the presence of at least two interaction sites for steroids (Hawkinson et al., 1994; A. Evers, personal communication) . Together, the data indicate that other potentiating sites, in addition to the one identified structurally so far, must be present on the receptor. The ability of enantiomers of natural steroids to modulate receptor function further suggests that the receptor possesses additional steroid binding sites.
This article has not been copyedited and formatted. The final version may differ from this version. In this study, we have examined the ability of an enantiomer pair, etiocholanolone and entetiocholanolone, to potentiate α1β2γ2L GABA A receptor function. The effects of the steroids on GABA-mediated activation were examined individually, or in combination with each other or additional steroids, and the ability of mutations to the transmembrane domains to block potentiation by these steroids was investigated. The major finding is that etiocholanolone and entetiocholanolone act via different kinetic mechanisms to potentiate the receptor function, and that the binding sites involved in mediating potentiation are distinct. potentiation by ent-etiocholanolone remained unaffected, although the midpoint of the doseresponse curve was shifted by the double mutation. These results are inconsistent with the idea that the same sites, in terms of structure, underlie modulation by natural steroids and entetiocholanolone because any manipulation that abolishes potentiation by 3α5βP should also block potentiation by ent-etiocholanolone. Instead, the results suggest that Sites A1 and A2 differ, in terms of structure, for 3α5βP and ent-etiocholanolone, although steroid interactions with either set of sites can produce kinetically indistinguishable effects.
Two matters deserve further discussion and, possibly, follow up experiments in the future.
First, the α1(Q241A) and α1(I238N) mutations, although fully blocking potentiation by etiocholanolone, also strongly reduced modulation by ent-etiocholanolone. Whether the mutations block one kinetic pathway fully leaving the other intact, or affect both kinetic pathways partially is unclear. A previous study (Hosie et al., 2006) suggested that the 241 site participates in signal transduction as well as steroid binding, thus suggesting that some reduction in steroid potentiation is to be expected irrespective of whether the drugs bind at the same site or not, as long as the steroids utilize the same signal transduction pathway. Similar to the double mutant, the expression levels of the transiently expressed α1(Q241A) containing receptor are low, precluding mechanistic single-channel studies.
Second, although several lines of evidence suggest multiple steroid binding sites on the GABA A receptor (see above), mutations to a single nexus, i.e., the α1(N407A/Y410F) double mutation, can block potentiation by a steroid which has a single effect (etiocholanolone, Site A2), as well as a steroid which has multiple kinetic effects (3α5βP, Sites A1, A2 and B). This finding is counterintuitive, and may suggest that the site defined by the 407/410 residues controls steroid access to multiple sites, or that steroid binding to this site allosterically controls steroid actions in other sites. In future studies it will also be important to test whether the steroid binding sites formed by the two α subunits within a receptor are equivalent, and if steroid binding to either site has the same functional effect.
Etiocholanolone has anticonvulsant activity in several seizure models in mice (Kaminski et al., 2005) , and in men, low levels of androgens including etiocholanolone have been correlated with temporal lobe epilepsy (Herzog et al., 1986) . However, treatment in the form of etiocholanolone injection is counterproductive because it induces the release of interleukin-1, an endogenous pyrogen in humans resulting in inflammation and fever (Watters et al., 1985) .
Therefore, studies on enantiomeric steroids may also help to provide a more selective, and thus clinically useful drug with the desirable GABAergic actions of etiocholanolone in the central nervous system but devoid of immunological side effects.
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